Department of Pediatrics

Division of Pediatric Hematology/Oncology

Articles, Patents and Intellectual Property

Abdulamid I, Kassab MS, Beck FWJ, Kaplan J, Prasad, AS. Zinc status and interleukin-2 production in cystic fibrosis. J Trace Elem Exp Med  12:15-23, 1999.

Amylon MD, Shuster J, Pullen J, Berard C, Link MP, Wharam M, Katz J, Yu A, Laver J, Ravindranath Y, Kurtzberg J, Desai S, Camitta B, Murphy SB: Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T-cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a Pediatric Oncology Group study. Leukemia 13:335-342, 1999.

Baynes RD, Dansey RD, Klein JK, Karanes C, Abella E, Cassells L, Wei WZ, Galy A, Wood G, Peters WP:  High dose chemotherapy and peripheral blood progenitor cell transplantation in patients with breast cancer.  Invited review.  Cancer Investigation (in press).

Cochran PK, Chauvenet AR, hart PS, de Graff SSN, Cushing B, Kroovand L, Wofford M:  Hereditary persistence of alpha-fetoprotein (AFP) in a child with testicular germ cell tumor.   Med Ped Oncol 32:436-437, 1999.

Coyne M, Lusher JM:  Hemophilia emergency care.  Emergency Med (in press).

Crowley J, Sarnaik S:  Imaging of sickle cell disease.  Pediatr Radiol 29:646-661, 1999

Cushing B, Giller R, Ablin A, Cohen L, Cullen J, Hawkins E, Heifetz SA, Krailo M, Lauer SJ, Marina N, Rao PV, Rescorla F, Vinocur CD, Weetman RM, Castleberry RP:  Surgical resection alone is effective treatment for ovarian immature teratoma in children and adolescents: a report of the Pediatric Oncology Group and the ChildrenŐs Cancer Group.  Amer J Obstet Gynecol 181:353-357, 1999.  

Hamre M, Williams JA, Chuba PT, Yap J, Smietana S, Sood S, Bhambhani K:  Early deaths associated with pediatric brain tumors.  Med Ped Oncol (in press).

Johnson RM, Panchoosingh H, Goyette G, Ravindranath Y: Increased erythrocyte deformability in fetal erythropoiesis and in erythrocytes deficient in Glucose-6-Phospate Dehydrogenase and other glycolytic enzymes.  Ped Res 45:106-113,1999.

Kalyanaraman M, Heidemann SM, Sarnaik AP, Meert KL, Sarnaik SA: Anti-s antibody associated delayed hemolytic transfusion reaction in sickle cell anemia. J Ped Hematol-Oncol  21(1):70-73, 1999.

Klein JP, Rey PM, Dansey R, Karanes C, Abella E, Cassells L, Hamm C, Flowers M, Couwlier C, Peters WP, and Baynes RD:  Cyclophosphamide and paclitaxel as initial or salvage regimen for the mobilization of peripheral blood progenitor cells.  Bone Marrow Transpl 24:959-963, 1999.

Kulkarni R, Lusher JM, Henry RC, Kallen DJ: Current practices regarding newborn intracranial haemorrhage an obstetrical care and mode of delivery of pregnant haemophilia carriers: a survey of obstetricians, neonatologists and hematologists in the United State, on behalf of the National Hemophilia FoundationŐs Medical and Scientific Advisory Council.  Haemophilia 5:410-415, 1999.

Kulkarni R, Lusher JM: Intracranial and extracranial hemorrhages in newborns with hemophilia: a review of the literature.  J Ped Hematol-Oncol  21(4):289-295, 1999.

Lusher JM:  Acute hemarthroses - the benefits of early vs. late treatment with recombinant Factor VIIa.  Semin Hematol (in press).

Lusher JM:  Gene therapy for hemophilia A and B: patient selection and follow-up: requirements for a cure.  Thromb Haemost 82:572-575, 1999.

Lusher JM:  Inhibitor antibodies to Factor VIII and Factor IX: management.  Semin Thrombos Haemost (in press).

Lusher JM:  Inhibitor development in prospective clinical trials with recombinant factor VIII preparations in previously untreated patients.  Vox Sang  77 (suppl. 1):9, 1999.

Lusher JM:  Inhibitor development with recombinant Factor VIII products: results of controlled clinical trials.  Haematologica (in press).

Lusher JM:  Inhibitors in young boys with haemophilia A and B.  BailliereŐs Clin Haematol (in press).

Lusher JM:  Low complication rate with implantable venous access devices (central lines).  Internat Monitor on Hemophilia 7(1):19-20, 1999. 

Lusher JM:  Recombinant Factor VIIa Đ a viewpoint.  Biodrugs 12:78-79, 1999.

Lusher JM:  Systemic causes of excessive uterine bleeding.  Semin Hematol 36(3; suppl. 4):10-20, 1999.

Lusher JM: Early intervention with NovoSeven: what are the benefits?  Haemophilia in press.

Marina N, Cushing B, Giller R, Cohen L, Lauer S, Ablin A, Weetman R, Cullen J, Rogers P, Vinocur C, Stolar C, Rescorla F, Hawkins E, Heifetz S, Rao PJ, Krailo M, Castleberry R:  Complete surgical excision is effective treatment for children with immature teratoma (+/- malignant elements): a Pediatric Oncology Group / ChildrenŐs Cancer Group Intergroup Study.  J Clin Oncol 17:2137-2143,1999.

Matherly LH, Taub JW:  Molecular and cellular correlates of Methotrexate response in childhood acute lymphoblastic leukemia.  Leukemia and Lymphoma 35:1-20, 1999.

Nadvi SZ, Kottamasu SR, Bawle E, Abella E:  Physiologic osteosclerosis versus osteopetrosis of the newborn.  Clin Pediatr 38:235-238, 1999.

Nadvi SZ, Sarnaik S, Ravindranath Y:  Association of seizures with meperidine in sickle cell disease.  Clin Pediatr 38:459-462, 1999.

Ozgen U, Savasan S, Buck S, Ravindranath Y Comparison of DiOC6(3) uptake and Annexin V labeling for quantification of apoptosis in leukemia cells and non-malignant T-lymphocytes from children.  Commun Clin Cytometry (in press).  Ozgen U, Savasan S, Stout M, Buck S, Ravindranath Y:  Further elucidation of mechanisms of resistance to vincristine in myeloid cells:  role of hypochlorous acid in degradation of vincristine by myeloperoxidase.  Leukemia (in press).

Paglia DE, Renner SW, Bhambhani K:  Differential effects of low-level lead exposure  on the natural isozymes of erythrocyte 51-nucleotidase.  Clin Biochem (in press).

Parsons SK, Gelber S, Cole BF, Ravindranath Y, Ogden A, Yeager AM, Chang M, Shuster J, Weinstein HJ, Gelber RD:  Quality-adjusted survival after treatment for acute myeloid leukemia in childhood: a q-twist analysis of the Pediatric Oncology Group study 8821.  J Clin Oncol (in press, 1999).

Prasad AS, Beck FWJ, Kaplan J, Chandrasekar PH, Ortega J, Fitzgerald JT, Swerdlow P. Effect of zinc supplementation on incidence of infections and hospital admissions in sickle cell disease. Am J Hematol  61:194-202, 1999.

Rabah R, Lucas DR, Farmer DL, Ryan JR, Ravindranath Y:  Primary liposarcoma of bone in an adolescent.  Internat J Surg Path 7(1):45-51,1999.

Ragni MV, Lusher JM, Koerper M, Manco-Johnson M, Krause DS:  Safety and immunogenicity of subcutaneous hepatitis A vaccine in children with hemophilia.  Haemophilia (in press).

Raimondi SC, Chang MN, Ravindranath Y, Behm FG, Gresik MV, Steuber CP, Weinstein HJ, Caroll AJ:  Chromosomal abnormalities in 478 children with acute myeloid leukemia: clinical characteristics and treatment outcome in a cooperative Pediatric Oncology Group study Đ POG 8821.  Blood 94(11):3707-3716, 1999.

Ravindranath Y, Chang M, Raimondi SC, Carroll A, Steuber CP, Camitta B, Weinstein JH:  Prognostic factors and patterns of failure in childhood acute myeloid leukemia (AML): analysis of children treated on Pediatric Oncology Group (POG) study 8821.  Hema Blood Transf (in press), 1999.

Ravindranath Y, Taub JW:  Down syndrome and acute myeloid leukemia.  Lessons learned form experience with high-dose Ara-C containing regimens. Adv Exp Med Biol  457:409-414, 1999.

Ravindranath Y:  Forty-five-year follow-up of a childhood leukemia survivor: serendipity or karma?  Med Pediatr Oncol 33(4): 409-410, 1999.

Seremetis S, Lusher JM, Abildgaard C, Kasper CK, Allred R, Hurst D, and The Kogenate Study Group:  Human recombinant DNA-derived antihaemophilic factor (factor VIII) in the treatment of haemophilia A: conclusions of a 5-year study of home therapy. Haemophilia 5:9-16,1999.

Taub JW, Huang X, Matherly LH, Stout ML, Buck SA, Massey GV, Becton DL, Chang MN, Weinstein JH, Ravindranath Y:  Expression of Chromosome 21-localized genes in acute myeloid leukemia: differences between Down Syndrome and non-Down Syndrome blast cells and relationship to in vitro sensitivity to cytosine arabinoside and daunorubicin.  Blood 94(4):1393-1400, 1999.

Thorland EC, Drost JB, Lusher JM, Warrier I, Shapiro A, Koerper MA, Dimichele D, Westman J, Key NS, Sommer SS:  Anaphylactic response to factor IX replacement therapy in haemophilia B patients: complete gene deletions confer the highest risk. Haemophilia 5:101-105,1999.

Unuvar A, Warrier I, Lusher, JM:  Immune tolerance induction in the treatment of paediatric haemophilia A patients with factor VIII inhibitors. Haemophilia  (in press).

Bhambhani K.  02/16/1999: U.S. Patent No. 5,871,947; awarded for ŇMethod for the Determination of Low Concentrations of Heavy MetalsÓ; Paglia DE, Renner SW, Bhambhani K, Nakatani M (through UCLA).

Books, Chapters and Reviews

Lusher JM:  Haemophilia A and B.  In: (Lilleyman, Hann, Blanchette, eds.) , Paediatric Haematology, 2nd edition, Churchill-Livingstone, London, 1999 (in press).

Lusher JM:  Treatment of the coagulation coagulopathies.  In: (Mintz PD, ed.), Practice Guidelines for Transfusion Therapy, AABB Press, Bethesda, MD, 1999, pp. 97-128. 

Ravindranath Y, Taub JW:  Down Syndrome and AML: Lessons learned from experience with high dose Ara-C containing regimens. In: Drug Resistance in leukemia and Lymphoma III, (Kaspers GJL, Pieters R, Veerman AJP, Eds.), Kluwer Academic / Plenum Publ., New York, 1999. 

Abstracts, Letters to the Editor and Articles in Non-Referred Journals

Abella E, Karanes C, Klein J, Dansey R, KuKuruga D, Nadeau T, Cassells L, Peter W, Baynes R:  Superior results following matched unrelated donor (MUD) bone marrow transplants (BMT) in severe aplastic anemia (AA) patients using a non-TBI containing preparative regimen. Presented at the IBMTR-ABMTR conference, Feb. 28-Mar. 6, 1999, Keystone, CO. Abstract Book of the IBMTR-ABMTR, p. 44; abstract # O-1, 1999.

Abella E, KuKurga D, Du W, Mohamed A, Bakdounes K, Nadue T, Karanes C, Klein J, Dansey R, Cassells L, Peters W, Baynes R:  Clinical comparison of variable number tandem repeats (VNTR), cytogenetics, and fluorescence in situ hybridization (FISH) in allogenenic stem cell transplant patients. Presented at the IBMTR-ABMTR conference, Feb. 28-Mar. 6, 1999, Keystone, CO. Abstract Book of the IBMTR-ABMTR, p. 27; abstract # A-1, 1999.

Cassells L, Dansey RD, Karanes C, Klein JL, Abella E, Peters WP, Baynes RD:  Unrelated donor bone marrow transplants in patients over the age of 45 years.  Presented at the 35th annual meeting of American Society of Clinical Oncology, May 15-18, 1999, Atlanta, GA.  Proceed of ASCO 18:51a, abstract # 192, 1999

Coppes MJ, Keays S, Yanofsky R, Bhambhani K, Jardine L, Luke B, Meyer W, Pritchard S, Silva M, Yim Y, Stewart  J, Moghrabi A:  Single intravenous (IV) dose dolasetron mesylate has equivalent antiemetic efficacy to IV ondansetron for emetogeneic chemotherapy in pediatric patients when both are use in combination with IV dexamethasone.  Presented at the Joint meeting of the International Society of Paediatric Oncology (SIOP) and the American Society of Pediatric Hematology/ Oncology, Sept. 13-18, 1999, Montreal, Quebec, Canada.  Med Ped Oncol 33(3):p. 163, abstract # 0-77, 1999. 

Dansey R, Karanes C, Abella S, Klein J, Cassells L, Peters W, Baynes R:  Unrelated donor transplants in patients over the age of 45 years. Presented at the IBMTR-ABMTR conference, Feb. 28-Mar. 6, 1999, Keystone, CO. Abstract Book of the IBMTR-ABMTR, p. 26; abstract # A-5, 1999.

Dansey R, Zielinsky I, Klein J, Karanes C, Abella S, Carrion R, Du W, Cassells L, Peters W, Baynes R: Optimization of peripheral blood stem cell collections using peripheral blood CD34 levels and routine high volume pheresis. Presented at the IBMTR-ABMTR conference, Feb. 28-Mar. 6, 1999, Keystone, CO. Abstract Book of the IBMTR-ABMTR, p. 34; abstract # B-9, 1999.

Dansey RD, de Maroto Rey P, Klein JL, Karanes C, Hamm C, Cassells L, Abella E, Peters WP, Du W, Baynes RD:  Autologous stem cell transplantation for relapsed/refractory HodgkinŐs Disease using cyclophosphamide, platinum and BCNU.  Proceed of ASCO 18:26a, abstract # 94, 1999. differences in blood counts are suggestive of genetic variability.  Ped Res 45:152A,abstract # 886, 1999.

Hamre MR, Chuba PJ, Yap J, Williams J, Ryan J:  Osteosarcoma (OS) as a second primary malignant neoplasm.  Proceed of ASCO 18:545a, abstract # 2103, 1999.

Laver JH, Barredo JC, Amylon M, Kurtzberg J, Camitta BM, Pullen J, Link M, Ravindranath Y:  Effects of cranial radiation in children with high-risk T-cell acute lymphoblastic leukemia: a Pediatric Oncology Group report.  Presented at the 35th annual meeting of Am. Soc. of Clinical Oncology, May 15-18, 1999, Atlanta, GA.  Proceed of ASCO 18:565a, abstract # 2180, 1999.

Lusher JM, Gringeri A, Hann I, Rodriguez D:  Safety, efficacy and inhibitor development in previously untreated patients (PUPs) treated exclusively with recombinant B domain deleted recombinant F VIII (BDD rF VIII).  Presented at the 41st annual meeting of the American Society of Hematology, New Orleans, LA, Dec. 3-7, 1999 (abstract published in Blood 94 (suppl 1),p. 234a-35a, abstract # 1037.

Lusher JM, Kreuz W, Gazengel C, Gorina E, Kellerman E, Vosburg E:  Inhibitor formation monitoring in pediatric patients with severe hemophilia A receiving a second-generation rF VIII concentrate formulated with sucrose.  Presented at the 41st annual meeting of the American Society of Hematology, New Orleans, LA, Dec. 3-7, 1999 (abstract published in Blood 94(10) (suppl 1),  238a, abstract # 1050.

Lusher JM, Spira G, Rodriguez D, and the ReFacto PUP Study Group:  A four-year update of safety and efficacy of an albumin-free formulated, B-domain deleted factor VIII (r-VIII SQ) in previously untreated patients with severe hemophilia A.  Presented at the XVII Congress of the International Society of Thrombosis & Haemostasis, August, 1999, Washington, D.C.  Thromb Haemost Aug., 1999, p. 472, abstract # 1492, 1999.

Matherly LH, Taub JW, Zhang L, Zhang Z, Witt T, Hukku B, Shah S, Ravindranath Y:  Acute lymphoblastic leukemia (ALL) cells with t(2;21) exhibit increased levels and activity of human reduced folate carrier (hRFC).  Presented at the Annual Meeting of the American Association for Cancer Research.  Philadelphia PA, Apr. 10-14, 1999.  Proc Am Assoc Cancer Res 40:1942a, 1999.

Ravindranath Y, Hamre M, Becton D, Buck S, Stout M, Thomas R, Chang M, Weinstein H: Multidrug resistance gene (MDR1) expression and cytotoxicity to daunorubicin and cytarabine in childhood acute myeloid leukemia (AML).  Presented at the 1999 Joint Meeting of the International Society of Pediatric Oncology (SIOP) and Amer. Soc. Of Pediatric Hem/Onc, Sept. 13-18, 1999, Montreal, Quebec, Canada.  Med Ped Oncol  33(3):148, abstract # O-11, 1999.

Ravindranath Y, Hamre M, Becton D, Buck S, Stout M, Thomas R, Chang M, Weinstein H: Multidrug resistance gene (MDR1) expression and cytotoxicity to daunorubicin and cytarabine in childhood acute myeloid leukemia (AML).  Presented at the 1999 Joint Meeting of the International Society of Pediatric Oncology (SIOP) and Amer. Soc. of Pediatric Hem/Onc, Sept. 13-18, 1999, Montreal, Quebec, Canada.  Med Ped Oncol 33(3): p.148, abstract # O-11, 1999.

Sarnaik S, Simpson PM, Hamre M, Williams JA, Ravindranath Y:  Distribution of ethnic differences in blood counts are suggestive of genetic variability.  Ped Res 45:152A, abstract # 886, 1999.

Savasan S, Buck S, Becton D, Weinstein H, Ravindranath Y: Cytotoxicity Assessment by Quantitating Drug-Induced Apoptosis and Drug Resistance Patterns in Childhood Acute Myeloid Leukemia (AML). Presented  at the 1999 ASH Meeting, New Orleans, LA, Dec. 3-7, 1999.  Blood 94 (suppl 1),p. 63a, abstract # 268.

Taub JW, Ge Y, Huang X, Stout ML, Dutcher JA, Mohammad RM, Ravindranath Y, Matherly LH:  Factors regulating expression of the chromosome 21-localized gene, cystathionine beta synthase, in Down Syndrome myeloblasts and its role in the high event-free survival rates of Down Syndrome patients with acute myeloid leukemia.  Presented at the 41st annual meeting of the American Society Of Hematology meeting, New Orleans, LA, Dec. 3-7, 1999. Blood 94 (suppl.1; part 1) 382a, abstract # 1698, 1999.

Taub JW, Roarty JD, Fontanesi J, Slovis TL, Trese MT, Ravindranath Y:  Neoadjuvant chemotherapy and local therapy improves the outcome of eye salvage in retinoblastoma: The ChildrenŐs Hospital of Michigan Experience, 1981-1998.  Presented at the International Congress of Ocular Oncology, Philadelphia, PA, May 2-6, 1999.

Unuvar A, Warrier I. Immune tolerance in the treatment of pediatric hemophilia A patients with F VIII inhibitors.  Presented at the XVIIth congress of the ISTH, Washington, DC, USA,  August 14-21, 1999.   Thromb Haemost (Suppl., Aug., 1999):131, abstract # 405.

Warrier I, Unuvar A.  Central nervous system bleeding in children with hemophilia.  Presented at the XVIIth congress of the ISTH, Washington, DC, USA,  August 14-21, 1999. Thrombos Haemost (Suppl., Aug., 1999):330, abstract # 1044.

Williams JA, Hamre M, Chuba PJ, Yap J, Smietana S, Sood S, Bhambhani K:  Early deaths associated with pediatric brain tumors.  Proceed of ASCO 18:573a, abstract # 2213, 1999.

Williams JA, Kintzel PE, Abella E, Klein J, Dansey R, Karanes C, Baynes R:  Ethanol toxicity with high-dose etoposide: a case report in two bone marrow transplant recipients. Presented at IBMTR-ABMTR conference, Feb. 28-Mar. 6,1999, Keystone, CO.  Abstract Book of the IBMTR-ABMTR,  p. 23; abstract # 82, 1999.

Yap J, Chuba PJ, Williams J, Aref A, Weiss L, Hamre M:  Breast cancer and the incidence rates of sarcoma as subsequent malignant neoplasm: a U.S. population-based analysis.  Proceed of ASCO 18:549a, abstract # 2120, 1999.

Back to Pediatrics